Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000040

Drug Information
NameVerapamil
SynonymsHMS1791L15; 2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-isopropylpentanenitrile, (+/-)-; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; NCI60_020143; Spectrum2_001740; nchembio.79-comp5; Isoptimo; nchembio.368-comp2; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; LS-174; Verapamilum; Verapamilo; Cordilox; (+/-)-VERAPAMIL; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; 52-53-9; KBio3_000465; KBio2_002801; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-; Verapamil [USAN:INN:BAN]; C27H38N2O4; CP-16533-1; NINDS_000399; D02356; KBio2_000233; Dilacoran; KBioGR_000233; NCGC00024710-04; Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-; CHEBI:9948; Verapamil (USAN/INN); BRD-A09533288-003-05-6; Veracim; KBio2_007479; CID2520; NSC272366; Verapamilum [INN-Latin]; Isoptin; Prestwick3_000141; KBioSS_000233; Iproveratril; L001330; HMS2089H17; Bio1_001403; Bio2_000713; alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; DivK1c_000399; KBio2_002343; AB00053495; Verapamil [USAN:BAN:INN]; Prestwick1_000141; Veraptin; alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Bio-0754; NCGC00024710-07; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (+-)-; CCRIS 6749; BPBio1_000268; Isotopin; KBio2_005369; Calcan; I06-0063; NCGC00016083-14; Calan; UNII-CJ0O37KU29; Verexamil; MolPort-000-721-258; KBioGR_001372; CHEMBL6966; NCGC00024710-05; BRD-A09533288-001-02-7; SPBio_001820; SPBio_002181; HMS1989L15; D-365; EINECS 200-145-1; Prestwick2_000141; DB00661; Verapamilo [INN-Spanish]; 56949-77-0; KBioGR_002343; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; cMAP_000023; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; STK538085; KBio2_004911; FT-0080127; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; NCGC00024710-08; BSPBio_001513; Prestwick0_000141; IDI1_033983; KBioSS_002346; Spectrum5_001786; KBio1_000399; C07188; EINECS 260-462-6; Spectrum4_000906; Vasolan; KBio3_002823; IDI1_000399; AC-16016; AC1L1DV5; BSPBio_002358; Lopac0_001237; (+-)-Verapamil; KBio3_000466; Drosteakard; NCGC00024710-09; NCGC00024710-06; Arpamyl; Dexverapamil; alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; BSPBio_000242; Bio1_000914; VERAPAMIL; Bio2_000233; Bio1_000425
Trade NameIsoptin; Verelan; Calan; Bosoptin; Covera-HS
CompanyPfizer Inc
IndicationHypertension and angina
[ICD9: 401, 413   ICD10: I10, I11, I12, I13, I15, I20]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-
8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,1
3-16H2,1-7H3
InChIKeySGTNSNPWRIOYBX-UHFFFAOYSA-N
Canonical SMILESCC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC    
Therapeutic ClassAnalgesics
CAS NumberCAS 52-53-9
FormulaC27H38N2O4
PubChem Compound IDCID 2520.
PubChem Substance IDSID 9397.
ChEBI9948;
SuperDrug ATC IDC08DA01
SuperDrug CAS ID000052539;
TargetVoltage-dependent T-type calcium channelBlocker[2][3]
Ref 1Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 2008 Feb;6(2):e26. To Reference
Ref 2Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93. To Reference
Ref 3Combination therapy and target organ protection in hypertension and diabetes mellitus. Am J Hypertens. 1997 Sep;10(9 Pt 2):198S-201S. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543